Does the media favor CTMX or AUPH?

In the previous week, CytomX Therapeutics had 1 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 2 mentions for CytomX Therapeutics and 1 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 0.50 beat CytomX Therapeutics' score of -0.33 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aurinia Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CTMX or TRVI?

In the previous week, Trevi Therapeutics had 2 more articles in the media than CytomX Therapeutics. MarketBeat recorded 4 mentions for Trevi Therapeutics and 2 mentions for CytomX Therapeutics. Trevi Therapeutics' average media sentiment score of 0.16 beat CytomX Therapeutics' score of -0.33 indicating that Trevi Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Trevi Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CTMX or PHVS?

In the previous week, Pharvaris had 4 more articles in the media than CytomX Therapeutics. MarketBeat recorded 6 mentions for Pharvaris and 2 mentions for CytomX Therapeutics. Pharvaris' average media sentiment score of 0.16 beat CytomX Therapeutics' score of -0.33 indicating that Pharvaris is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pharvaris 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CTMX or OCUL?

In the previous week, Ocular Therapeutix had 10 more articles in the media than CytomX Therapeutics. MarketBeat recorded 12 mentions for Ocular Therapeutix and 2 mentions for CytomX Therapeutics. Ocular Therapeutix's average media sentiment score of 0.46 beat CytomX Therapeutics' score of -0.33 indicating that Ocular Therapeutix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ocular Therapeutix 0 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

CytomX Therapeutics (CTMX) Competitors

$3.15 +0.11 (+3.62%)

Closing price 06/23/2026 04:00 PM Eastern

Extended Trading

$3.18 +0.03 (+0.92%)

As of 06/23/2026 07:55 PM Eastern

Compare

CTMX vs. AUPH, TRVI, PHVS, HRMY, and OCUL

Should you buy CytomX Therapeutics stock or one of its competitors? MarketBeat compares CytomX Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CytomX Therapeutics include Aurinia Pharmaceuticals (AUPH), Trevi Therapeutics (TRVI), Pharvaris (PHVS), Harmony Biosciences (HRMY), and Ocular Therapeutix (OCUL). These companies are all part of the "pharmaceutical products" industry.

How does CytomX Therapeutics compare to Aurinia Pharmaceuticals?

CytomX Therapeutics (NASDAQ:CTMX) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

In the previous week, CytomX Therapeutics had 1 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 2 mentions for CytomX Therapeutics and 1 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 0.50 beat CytomX Therapeutics' score of -0.33 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CytomX Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aurinia Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

67.8% of CytomX Therapeutics shares are owned by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. 3.8% of CytomX Therapeutics shares are owned by insiders. Comparatively, 12.2% of Aurinia Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

CytomX Therapeutics presently has a consensus target price of $12.10, suggesting a potential upside of 284.13%. Aurinia Pharmaceuticals has a consensus target price of $17.25, suggesting a potential downside of 3.52%. Given CytomX Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe CytomX Therapeutics is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Aurinia Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Aurinia Pharmaceuticals has higher revenue and earnings than CytomX Therapeutics. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$76.20M	7.04	-$17.37M	-$0.41	N/A
Aurinia Pharmaceuticals	$283.05M	8.12	$287.20M	$2.17	8.24

Aurinia Pharmaceuticals has a net margin of 99.97% compared to CytomX Therapeutics' net margin of -166.40%. Aurinia Pharmaceuticals' return on equity of 26.62% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-166.40%	-36.61%	-28.02%
Aurinia Pharmaceuticals	99.97%	26.62%	19.65%

CytomX Therapeutics has a beta of 2.08, suggesting that its stock price is 108% more volatile than the broader market. Comparatively, Aurinia Pharmaceuticals has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market.

Summary

Aurinia Pharmaceuticals beats CytomX Therapeutics on 10 of the 17 factors compared between the two stocks.

How does CytomX Therapeutics compare to Trevi Therapeutics?

CytomX Therapeutics (NASDAQ:CTMX) and Trevi Therapeutics (NASDAQ:TRVI) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, media sentiment and earnings.

Trevi Therapeutics has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -166.40%. Trevi Therapeutics' return on equity of -24.53% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-166.40%	-36.61%	-28.02%
Trevi Therapeutics	N/A	-24.53%	-23.37%

CytomX Therapeutics has higher revenue and earnings than Trevi Therapeutics. Trevi Therapeutics is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$76.20M	7.04	-$17.37M	-$0.41	N/A
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.32	N/A

67.8% of CytomX Therapeutics shares are owned by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are owned by institutional investors. 3.8% of CytomX Therapeutics shares are owned by insiders. Comparatively, 18.3% of Trevi Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

CytomX Therapeutics has a beta of 2.08, suggesting that its share price is 108% more volatile than the broader market. Comparatively, Trevi Therapeutics has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market.

CytomX Therapeutics currently has a consensus target price of $12.10, suggesting a potential upside of 284.13%. Trevi Therapeutics has a consensus target price of $22.90, suggesting a potential upside of 31.76%. Given CytomX Therapeutics' higher possible upside, analysts clearly believe CytomX Therapeutics is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Trevi Therapeutics had 2 more articles in the media than CytomX Therapeutics. MarketBeat recorded 4 mentions for Trevi Therapeutics and 2 mentions for CytomX Therapeutics. Trevi Therapeutics' average media sentiment score of 0.16 beat CytomX Therapeutics' score of -0.33 indicating that Trevi Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CytomX Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Trevi Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Trevi Therapeutics beats CytomX Therapeutics on 10 of the 15 factors compared between the two stocks.

How does CytomX Therapeutics compare to Pharvaris?

CytomX Therapeutics (NASDAQ:CTMX) and Pharvaris (NASDAQ:PHVS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

In the previous week, Pharvaris had 4 more articles in the media than CytomX Therapeutics. MarketBeat recorded 6 mentions for Pharvaris and 2 mentions for CytomX Therapeutics. Pharvaris' average media sentiment score of 0.16 beat CytomX Therapeutics' score of -0.33 indicating that Pharvaris is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CytomX Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pharvaris	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CytomX Therapeutics has a beta of 2.08, meaning that its stock price is 108% more volatile than the broader market. Comparatively, Pharvaris has a beta of -2.35, meaning that its stock price is 335% less volatile than the broader market.

CytomX Therapeutics has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$76.20M	7.04	-$17.37M	-$0.41	N/A
Pharvaris	N/A	N/A	-$198.79M	-$3.18	N/A

Pharvaris has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -166.40%. CytomX Therapeutics' return on equity of -36.61% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-166.40%	-36.61%	-28.02%
Pharvaris	N/A	-67.56%	-61.13%

67.8% of CytomX Therapeutics shares are owned by institutional investors. 3.8% of CytomX Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

CytomX Therapeutics currently has a consensus target price of $12.10, indicating a potential upside of 284.13%. Pharvaris has a consensus target price of $49.18, indicating a potential upside of 48.18%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe CytomX Therapeutics is more favorable than Pharvaris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Pharvaris	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Summary

CytomX Therapeutics beats Pharvaris on 12 of the 16 factors compared between the two stocks.

How does CytomX Therapeutics compare to Harmony Biosciences?

CytomX Therapeutics (NASDAQ:CTMX) and Harmony Biosciences (NASDAQ:HRMY) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

67.8% of CytomX Therapeutics shares are held by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are held by institutional investors. 3.8% of CytomX Therapeutics shares are held by company insiders. Comparatively, 11.0% of Harmony Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Harmony Biosciences has higher revenue and earnings than CytomX Therapeutics. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$76.20M	7.04	-$17.37M	-$0.41	N/A
Harmony Biosciences	$868.45M	2.28	$158.69M	$2.48	13.77

In the previous week, CytomX Therapeutics had 2 more articles in the media than Harmony Biosciences. MarketBeat recorded 2 mentions for CytomX Therapeutics and 0 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 0.00 beat CytomX Therapeutics' score of -0.33 indicating that Harmony Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
CytomX Therapeutics	Neutral
Harmony Biosciences	Neutral

Harmony Biosciences has a net margin of 16.20% compared to CytomX Therapeutics' net margin of -166.40%. Harmony Biosciences' return on equity of 17.19% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-166.40%	-36.61%	-28.02%
Harmony Biosciences	16.20%	17.19%	11.99%

CytomX Therapeutics presently has a consensus price target of $12.10, suggesting a potential upside of 284.13%. Harmony Biosciences has a consensus price target of $40.89, suggesting a potential upside of 19.70%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe CytomX Therapeutics is more favorable than Harmony Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Harmony Biosciences	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27

CytomX Therapeutics has a beta of 2.08, meaning that its share price is 108% more volatile than the broader market. Comparatively, Harmony Biosciences has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market.

Summary

Harmony Biosciences beats CytomX Therapeutics on 10 of the 17 factors compared between the two stocks.

How does CytomX Therapeutics compare to Ocular Therapeutix?

CytomX Therapeutics (NASDAQ:CTMX) and Ocular Therapeutix (NASDAQ:OCUL) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings.

CytomX Therapeutics has a net margin of -166.40% compared to Ocular Therapeutix's net margin of -558.24%. CytomX Therapeutics' return on equity of -36.61% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-166.40%	-36.61%	-28.02%
Ocular Therapeutix	-558.24%	-64.28%	-48.15%

67.8% of CytomX Therapeutics shares are owned by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are owned by institutional investors. 3.8% of CytomX Therapeutics shares are owned by insiders. Comparatively, 3.1% of Ocular Therapeutix shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

CytomX Therapeutics has higher revenue and earnings than Ocular Therapeutix. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$76.20M	7.04	-$17.37M	-$0.41	N/A
Ocular Therapeutix	$51.95M	42.61	-$265.94M	-$1.46	N/A

In the previous week, Ocular Therapeutix had 10 more articles in the media than CytomX Therapeutics. MarketBeat recorded 12 mentions for Ocular Therapeutix and 2 mentions for CytomX Therapeutics. Ocular Therapeutix's average media sentiment score of 0.46 beat CytomX Therapeutics' score of -0.33 indicating that Ocular Therapeutix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CytomX Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ocular Therapeutix	0 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CytomX Therapeutics presently has a consensus target price of $12.10, suggesting a potential upside of 284.13%. Ocular Therapeutix has a consensus target price of $24.89, suggesting a potential upside of 146.18%. Given CytomX Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe CytomX Therapeutics is more favorable than Ocular Therapeutix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

CytomX Therapeutics has a beta of 2.08, indicating that its stock price is 108% more volatile than the broader market. Comparatively, Ocular Therapeutix has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market.

Summary

CytomX Therapeutics beats Ocular Therapeutix on 12 of the 17 factors compared between the two stocks.

Get CytomX Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTMX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CTMX vs. The Competition

Export

Metric	CytomX Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$517.37M	$3.45B	$6.44B	$12.39B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-7.68	19.75	24.90	23.99
Price / Sales	7.04	330.90	527.78	108.89
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	5.43	8.29	10.79	6.50
Net Income	-$17.37M	$23.85M	$3.56B	$336.88M
7 Day Performance	6.42%	2.87%	1.00%	-0.14%
1 Month Performance	-16.22%	2.19%	0.42%	0.77%
1 Year Performance	47.20%	55.48%	29.70%	28.49%

CytomX Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CTMX CytomX Therapeutics	2.6608 of 5 stars	$3.15 +3.6%	$12.10 +284.1%	+45.8%	$517.37M	$76.20M	N/A	170
AUPH Aurinia Pharmaceuticals	1.547 of 5 stars	$16.00 +1.1%	$17.25 +7.8%	+128.4%	$2.03B	$283.05M	7.37	300
TRVI Trevi Therapeutics	2.7763 of 5 stars	$14.66 +3.2%	$22.90 +56.2%	+202.3%	$2.02B	N/A	N/A	20	News Coverage
PHVS Pharvaris	3.3846 of 5 stars	$31.54 +2.7%	$49.18 +55.9%	+90.5%	$2.01B	N/A	N/A	30
HRMY Harmony Biosciences	4.0737 of 5 stars	$34.18 -0.8%	$40.89 +19.6%	+7.0%	$1.99B	$868.45M	13.78	200

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CTMX) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CytomX Therapeutics (CTMX) Competitors

CTMX vs. AUPH, TRVI, PHVS, HRMY, and OCUL

How does CytomX Therapeutics compare to Aurinia Pharmaceuticals?

Summary

How does CytomX Therapeutics compare to Trevi Therapeutics?

Summary

How does CytomX Therapeutics compare to Pharvaris?

Summary

How does CytomX Therapeutics compare to Harmony Biosciences?

Summary

How does CytomX Therapeutics compare to Ocular Therapeutix?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTMX vs. The Competition

CytomX Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CytomX Therapeutics (CTMX) Competitors

CTMX vs. AUPH, TRVI, PHVS, HRMY, and OCUL

How does CytomX Therapeutics compare to Aurinia Pharmaceuticals?

Does the media favor CTMX or AUPH?

Do institutionals and insiders have more ownership in CTMX or AUPH?

Do analysts prefer CTMX or AUPH?

Which has higher valuation & earnings, CTMX or AUPH?

Is CTMX or AUPH more profitable?

Which has more risk & volatility, CTMX or AUPH?

Summary

How does CytomX Therapeutics compare to Trevi Therapeutics?

Is CTMX or TRVI more profitable?

Which has stronger valuation and earnings, CTMX or TRVI?

Do insiders & institutionals have more ownership in CTMX or TRVI?

Which has more risk and volatility, CTMX or TRVI?

Do analysts prefer CTMX or TRVI?

Does the media refer more to CTMX or TRVI?

Summary

How does CytomX Therapeutics compare to Pharvaris?

Does the media favor CTMX or PHVS?

Which has more risk and volatility, CTMX or PHVS?

Which has stronger earnings and valuation, CTMX or PHVS?

Is CTMX or PHVS more profitable?

Do institutionals and insiders believe in CTMX or PHVS?

Do analysts recommend CTMX or PHVS?

Summary

How does CytomX Therapeutics compare to Harmony Biosciences?

Do insiders & institutionals hold more shares of CTMX or HRMY?

Which has higher valuation & earnings, CTMX or HRMY?

Does the media refer more to CTMX or HRMY?

Is CTMX or HRMY more profitable?

Do analysts recommend CTMX or HRMY?

Which has more risk & volatility, CTMX or HRMY?

Summary

How does CytomX Therapeutics compare to Ocular Therapeutix?

Is CTMX or OCUL more profitable?

Do insiders and institutionals hold more shares of CTMX or OCUL?

Which has higher earnings & valuation, CTMX or OCUL?

Does the media favor CTMX or OCUL?

Do analysts rate CTMX or OCUL?

Which has more risk & volatility, CTMX or OCUL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTMX vs. The Competition

CytomX Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools